Insiders · SYRE

Cameron Turtle

Chief Executive Officer, Director at Spyre Therapeutics, Inc. (SYRE) since June 2023

Cameron Turtle has filed 23 insider reports with the SEC since January 2021, as chief Executive Officer and director at Spyre Therapeutics, Inc. (SYRE), director at Damora Therapeutics, Inc. (DMRA) and director at Oruka Therapeutics, Inc. (ORKA) and at 1 more company. In the last 12 months Cameron Turtle sold $10.3M of stock on the open market. In the latest filing, on October 3, 2026, Cameron Turtle sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) for $1.38M at an average of $92.01.

Filings
23
Companies
4
Bought on market
None
Sold on market
$11.4M

Companies where Cameron Turtle is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Spyre Therapeutics, Inc. logo
SYRE
Spyre Therapeutics, Inc.
Chief Executive Officer, Directorsince June 2023537,540$11.4M$93.81Oct 3, 2026
Damora Therapeutics, Inc. logo
DMRA
Damora Therapeutics, Inc.
Directorsince March 2026$22.56Mar 25, 2026
Oruka Therapeutics, Inc. logo
ORKA
Oruka Therapeutics, Inc.
Directorsince August 2024$96.32Jun 3, 2025
Eidos Therapeutics, Inc. logo
EIDX
Eidos Therapeutics, Inc.
Officer0Jan 29, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Cameron Turtle with

Other insiders at the same companies

Questions about Cameron Turtle

What is Cameron Turtle's role at Spyre Therapeutics, Inc.?
Cameron Turtle reports to the SEC as chief Executive Officer and director at Spyre Therapeutics, Inc. (SYRE), according to the latest filing on October 3, 2026. Cameron Turtle has also filed as director at Damora Therapeutics, Inc. (DMRA), director at Oruka Therapeutics, Inc. (ORKA) and officer at Eidos Therapeutics, Inc. (EIDX).
How many shares does Cameron Turtle own?
After the latest filing that states it, Cameron Turtle directly owned 537,540 shares of Spyre Therapeutics, Inc. (SYRE). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Cameron Turtle bought or sold stock recently?
The most recent open-market sale was on October 1, 2026: sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) for $1.38M at an average of $92.01.
How do I get alerts when Cameron Turtle files?
Follow Cameron Turtle on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Cameron Turtle filed 2 times in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Cameron Turtle (SEC CIK 0001758363). Totals count each trade once, skipping amendments whose original is on file, from Jan 29, 2021 on. View on SEC EDGAR